For optimal T-cell–mediated anti-tumor immunity, T cells must recognize an antigen presented on major histocompatibility complexes (MHC) through the T-cell receptor (TCR) and receive a co-stimulatory signal through CD28 engagement with CD80/CD86. Here, CD86 is linked to neoplasm.